Otsuka And Lundbeck Issue Statement On U.S. FDA Advisory Committee Meeting On REXULTI For The Treatment Of Adults With PTSD
22/07/2025 24:33
July 22 (Reuters) - Otsuka Holdings Co Ltd 4578.T: OTSUKA HOLDINGS CO LTD - OTSUKA AND LUNDBECK ISSUE STATEMENT ON U.S. FDA ADVISORY COMMITTEE MEETING ON REXULTI FOR THE TREATMENT OF ADULTS WITH PTSD Source text: ID:nTSsu7e53e Further company coverage: 4578.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug